The Topographical Model of Multiple Sclerosis: A New Visualization of Disease Course (P4.013)

Abstract

OBJECTIVE: Develop a new unified MS clinical course model. BACKGROUND: Both inflammatory (relapsing) and neurodegenerative (progressive) processes contribute to MS disease course, but neither the relationship between them, nor the spectrum of clinical heterogeneity, is fully characterized in current clinical course categories. We have previously shown both diagnostic and prognostic uncertainty inherent in applying these categories to individual patients. A conceptually lucid, biologically informed model could build on these categories to encompass the admixture of factors underlying MS disease course. DESIGN/METHODS: The model design encapsulates five factors: topographical distribution of lesions and relapses they cause; relapse frequency, severity, and recovery; and progression rate. The model visually depicts the interplay of factors utilizing 3D animated renderings.The CNS is represented as a pool, with a shallow end and a deep end. Spinal cord and optic nerves occupy the shallow end, the posterior fossa comprises the middle, and the cerebral hemispheres constitute the deep end, each having increasing amounts of functional reserve. MS lesions rise up as topographical peaks from the pool floor. The water's surface depicts the clinical threshold: lesions below the surface are clinically silent; those that cross it cause clinical relapses. Progression is depicted as the slowly dropping water level, representing depletion of functional capacity. Thus, like symptom recrudescence in Uhthoff's phenomenon, progression clinically takes the form of prior relapses/lesions, incrementally revealing above the surface the underlying lesion topography. RESULTS: A dynamic, 3D-rendered visualization of the topographical model will be shown. Quantifiable clinical and MRI correlates of the depicted factors will be elucidated. CONCLUSIONS: This model depicts disease course in a clinically nuanced way that complements the clinical course categories. Expressed mathematically, the prognostic/predictive implications can be empirically tested, including application to clinical trial datasets. This new conceptualization of disease course may have bench and clinical MS research implications.

Disclosure: Dr. Krieger has received personal compensation for activities with Acorda Therapeutics, Bayer HealthCare, Biogen Idec, EMD Serono, Genzyme, Questcor Pharmaceuticals, and Teva Neuroscience as a consultant and/or advisory board member.